ArticleSLAS discovery : advancing life sciences R & D2026
Application of a MALDI mass spectrometry assay to identify covalent fragments targeting the methyl-lysine reader protein MPP8.
Article in SLAS discovery : advancing life sciences R & D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In recent decades, the development of targeted covalent inhibitors (TCIs) has significantly advanced, as evidenced by the increasing number of FDA approved drugs with covalent mechanisms of action. This study focuses on the application of a robust and efficient screening platform to identify covalent fragments that modify the methyl-lysine reader protein M-phase phosphoprotein 8 (MPP8). Using a commercially available covalent fragment library with various electrophile-based warheads, we screened for fragments that covalently label MPP8 using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Follow-up validation and prioritization studies involving evaluation of the reactivity of hit fragments with glutathione led to the identification of two novel acrylamide-containing fragments that covalently label MPP8 at cysteine 99, which is adjacent to the methyl-lysine binding pocket. These results emphasize the value of efficient screening approaches in discovering novel covalent fragments for challenging targets and demonstrate the potential for developing covalent antagonists targeting MPP8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.